TOBY Secures US FDA Breakthrough Device Designation for Urine-Based Alzheimer’s Disease Test

Why It Matters

A non‑invasive, low‑cost diagnostic could accelerate early Alzheimer’s detection, reducing reliance on expensive imaging and invasive procedures, and reshaping the care pathway for millions of patients.

Key Takeaways

• FDA grants Breakthrough Device status to TOBY's AD urine test.
• Test analyzes urinary VOCs with mass spectrometry and AI algorithms.
• Targets adults 50+ with cognitive impairment symptoms.
• Expands TOBY's portfolio beyond oncology into neurodegeneration.
• Plans further clinical validation and continued FDA collaboration.

Pulse Analysis

Alzheimer’s disease remains a leading cause of dementia, yet early diagnosis is hampered by invasive lumbar punctures and expensive PET scans. Clinicians rely on biomarkers in cerebrospinal fluid or costly imaging to confirm pathology, creating barriers for routine screening. The U.S. Food and Drug Administration’s Breakthrough Device Designation (BDD) is intended to accelerate development of technologies that address unmet medical needs. By awarding BDD to TOBY’s urine‑based test, the agency signals confidence that a simpler, non‑invasive assay could reshape the diagnostic pathway for patients over 50.

The TOBY test leverages volatile organic compound (VOC) signatures in urine, captured through high‑resolution mass spectrometry and interpreted by proprietary machine‑learning models. Early studies suggest distinct VOC patterns correlate with amyloid and tau pathology, enabling a blood‑type convenience without sacrificing analytical depth. Compared with lumbar puncture, urine collection is painless, low‑cost, and amenable to large‑scale screening programs. If validated, the assay could provide clinicians with a rapid triage tool, directing high‑risk individuals toward confirmatory imaging while sparing low‑risk patients unnecessary procedures.

Beyond the scientific promise, the designation expands TOBY’s pipeline, which previously focused on multi‑cancer urine diagnostics, into the neuro‑degenerative arena. Continued collaboration with the FDA will guide pivotal clinical trials, data collection, and eventual market clearance. Successful commercialization could generate a new revenue stream and position TOBY as a leader in liquid‑biopsy diagnostics across multiple disease classes. For the broader healthcare system, a cost‑effective urine test may lower diagnostic expenditures, accelerate therapeutic intervention, and ultimately improve outcomes for millions facing cognitive decline.